Magic mushroom compound tested for Parkinson's depression
NCT ID NCT07610369
First seen Jun 01, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This phase 2 trial tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can improve depression in people with Parkinson's disease. Forty participants will receive a low to high dose with psychological support. The study measures changes in depression severity and tracks any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
New Haven, Connecticut, 06510, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If it works, this could point toward a new treatment for depression in people with Parkinson's disease.
What could go wrong
This is a small, early-phase trial with only 40 people. It may not show clear benefit, and psilocybin can cause temporary anxiety or confusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.